Viz.ai vs Aidoc

Yes, Viz.ai has a higher valuation ($1.2B) compared to Aidoc (N/A).

Viz.ai raised $289M while Aidoc raised $370M.

Aidoc has the higher Awaira Score of 67.

Viz.ai: Viz.ai is an artificial intelligence healthcare company founded in 2016 that develops clinical decision support software for medical imaging analysis. The company specializes in AI-powered diagnostic tools that assist radiologists and emergency physicians in identifying acute neurological and cardiovascular conditions from medical imaging scans. Viz.ai's core platform uses deep learning algorithms to detect conditions such as stroke, pulmonary embolism, and aortic dissection, prioritizing urgent cases and flagging them for immediate physician review. The company's primary products include stroke detection software and platforms for identifying other time-critical conditions in emergency departments. Viz.ai operates within the broader clinical AI segment, competing with companies developing similar diagnostic imaging solutions. The platform integrates into existing hospital workflows and imaging infrastructure, providing real-time alerts to clinicians. Viz.ai has achieved significant market validation, with its technology adopted across numerous healthcare systems in the United States. The company raised Series D funding at a $1.2 billion valuation, reflecting investor confidence in the clinical AI market. Total funding reached $289 million across multiple rounds. The company's growth trajectory demonstrates expanded adoption among major hospital networks and healthcare providers seeking to improve diagnostic speed and clinical outcomes for emergency conditions. Viz.ai focuses specifically on time-critical emergency conditions where AI-assisted early detection directly impacts patient outcomes and hospital operations.. Aidoc: Aidoc is an Israeli artificial intelligence company founded in 2016 that develops clinical decision support software for radiology and medical imaging. The platform uses deep learning algorithms to analyze medical images, prioritize critical findings, and alert radiologists to potential abnormalities, particularly focusing on conditions requiring urgent intervention. Aidoc's core offering integrates into existing hospital workflows and PACS systems, enabling radiologists to identify and triage high-risk cases more efficiently. The company operates in the clinical AI segment, competing with firms like Zebra Medical Vision and Enlitic in automated imaging analysis. Aidoc's technology addresses the growing bottleneck of radiologist workload and diagnostic delays by automating preliminary image screening and flagging priority cases. The platform reportedly covers multiple pathologies including stroke, pulmonary embolism, and other acute conditions. As of the latest available data, Aidoc has secured $370 million in total funding through Series D stage, though its valuation remains not disclosed. The company has expanded internationally and serves healthcare institutions across multiple regions. Aidoc's growth trajectory reflects increasing institutional adoption of AI-assisted diagnostic tools in radiology departments globally, driven by workforce shortages and demand for faster diagnostic turnaround times in clinical settings. Aidoc focuses on clinical workflow integration rather than replacement, embedding AI directly into existing radiology infrastructure to accelerate diagnostic processes..

Both were founded in 2016.